Latest filings (excl ownership)
15-12B
Securities registration termination
10 Jun 22
EFFECT
Notice of effectiveness
2 Jun 22
25-NSE
Exchange delisting
31 May 22
S-8 POS
Registration of securities for employees (post-effective amendment)
31 May 22
S-8 POS
Registration of securities for employees (post-effective amendment)
31 May 22
S-8 POS
Registration of securities for employees (post-effective amendment)
31 May 22
POS AM
Prospectus update (post-effective amendment)
31 May 22
8-K
Completion of Acquisition or Disposition of Assets
31 May 22
SC 14D9/A
Tender offer solicitation (amended)
31 May 22
SC TO-T/A
Third party tender offer statement (amended)
31 May 22
SC TO-T/A
Third party tender offer statement (amended)
20 May 22
SC 14D9/A
Tender offer solicitation (amended)
20 May 22
10-Q
2022 Q1
Quarterly report
12 May 22
8-K
Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update
12 May 22
SC 14D9/A
Tender offer solicitation (amended)
11 May 22
SC TO-T/A
Third party tender offer statement (amended)
11 May 22
SC 14D9
Tender offer solicitation
2 May 22
SC TO-T
Third party tender offer statement
2 May 22
10-K/A
2021 FY
Annual report (amended)
29 Apr 22
SC14D9C
Written communication relating to third party tender offer
20 Apr 22
SC14D9C
Written communication relating to third party tender offer
20 Apr 22
8-K
Tender and Support Agreement
19 Apr 22
SC TO-C
Information about tender offer
19 Apr 22
SC14D9C
Written communication relating to third party tender offer
19 Apr 22
8-K
Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
19 Apr 22
10-K
2021 FY
Annual report
30 Mar 22
8-K
Checkmate Pharmaceuticals Announces Full Year 2021 Financial Results
30 Mar 22
S-8
Registration of securities for employees
29 Mar 22
8-K
Departure of Directors or Certain Officers
1 Mar 22
8-K
Checkmate Pharmaceuticals Appoints Alan Bash as President and CEO
9 Feb 22
8-K
Departure of Directors or Certain Officers
1 Feb 22
8-K
Nilesh Kumar, Ph.D. departs Board of Directors upon transition to new role at Wellington Management
21 Dec 21
8-K
Regulation FD Disclosure
14 Dec 21
10-Q
2021 Q3
Quarterly report
12 Nov 21
8-K
Checkmate Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update
12 Nov 21
8-K
Checkmate Pharmaceuticals Announces CEO Transition
27 Oct 21
8-K
Regulation FD Disclosure
4 Oct 21
EFFECT
Notice of effectiveness
16 Sep 21
CORRESP
Correspondence with SEC
13 Sep 21
UPLOAD
Letter from SEC
13 Sep 21
Latest ownership filings
SC 13G/A
venBio Global Strategic Fund II L.P.
7 Jun 22
SC 13D/A
GARDNER LEWIS ASSET MANAGEMENT L P
7 Jun 22
SC 13D/A
Novo Holdings A/S
3 Jun 22
SC 13D
GARDNER LEWIS ASSET MANAGEMENT L P
3 Jun 22
4
MICHAEL POWELL
31 May 22
4
Keith T. Flaherty
31 May 22
4
Oren Isacoff
31 May 22
4
Peter Colabuono
31 May 22
4
Joy Yan
31 May 22
4
Robert Dolski
31 May 22
4
James Wooldridge
31 May 22
4
Jon Marc Wigginton
31 May 22
4
Alan Fuhrman
31 May 22
4
ALAN BASH
31 May 22
4
COREY S GOODMAN
17 May 22
4
COREY S GOODMAN
12 May 22
SC 13D/A
Novo Holdings A/S
11 May 22
4
COREY S GOODMAN
9 May 22
SC 13G/A
venBio Global Strategic Fund II L.P.
5 May 22
4
COREY S GOODMAN
4 May 22
4
COREY S GOODMAN
29 Apr 22
4
James Wooldridge
28 Apr 22
4
COREY S GOODMAN
26 Apr 22
4
COREY S GOODMAN
21 Apr 22
4
ALAN BASH
2 Mar 22
3
ALAN BASH
2 Mar 22
4
Holdings A/S Novo
25 Feb 22
SC 13G
Decheng Capital Management III (Cayman), LLC
14 Feb 22
SC 13G/A
CLOUGH CAPITAL PARTNERS L P
14 Feb 22
4
Jon Marc Wigginton
1 Feb 22
3
Jon Marc Wigginton
1 Feb 22
4
Robert Dolski
31 Jan 22
4
James Wooldridge
31 Jan 22
4
Joy Yan
17 Dec 21
3
Joy Yan
17 Dec 21
SC 13D/A
Novo Holdings A/S
1 Nov 21
4
Alan Fuhrman
29 Oct 21
4
MICHAEL POWELL
10 Aug 21
4
Robert Dolski
6 Aug 21
4
Kleem Chaudhary
6 Aug 21